Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vaxcyte, Inc. - Common Stock (NQ:PCVX)

48.56 -0.20 (-0.41%)
Streaming Delayed Price Updated: 11:23 AM EDT, Jun 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 180,457
Open 48.70
Bid (Size) 48.52 (200)
Ask (Size) 48.60 (100)
Prev. Close 48.76
Today's Range 48.05 - 49.19
52wk Range 29.08 - 65.00
Shares Outstanding 93,706,790
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Trevi Therapeutics Is Up 100%, Pivotal bioVenture Adds Anyway. Here's Why That Matters. ↗
This clinical-stage biotech targets chronic pruritus and cough with its lead therapy for neurologically mediated diseases. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Vaxcyte Doses First Participant in Phase 1 Study Evaluating VAX-A1 for the Prevention of Disease Caused by Group A Streptococcus in Healthy Adults
From Vaxcyte, Inc.
Via GlobeNewswire

Performance

YTD
+4.5%
+4.5%
1 Month
-12.7%
-12.7%
3 Month
-16.6%
-16.6%
6 Month
+5.4%
+5.4%
1 Year
+43.5%
+43.5%

More News

Read More
News headline image
This Biotech Is Up 60%. A Top Healthcare Fund Just Bought Another $11 Million ↗
Via The Motley Fool
Topics Regulatory Compliance
Vaxcyte Inc (NASDAQ:PCVX) Reports Q4 2025 Results, Highlights Phase 3 Progress and Strong Cash Position ↗
Via Chartmill
News headline image
This Biotech Stock Is Up 355%. One Fund Added a $169 Million Position Last Quarter ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Dyne Therapeutics Is Up 40%, but One Biotech Fund Just Disclosed Selling $14 Million Worth of Shares ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
What This Fund’s $14 Million Ocular Therapeutix Exit Could Signal for Investors ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Biotech Fund Sells $44.5 Million Erasca Stake After Massive 700% Rally ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Vaxcyte Reports First Quarter 2026 Financial Results and Provides Business Update
From Vaxcyte, Inc.
Via GlobeNewswire
News headline image
Vaxcyte to Present at the 25th Annual Needham Virtual Healthcare Conference
From Vaxcyte, Inc.
Via GlobeNewswire
News headline image
Vaxcyte Completes Enrollment of OPUS-1 and OPUS-2 Phase 3 Trials Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults
From Vaxcyte, Inc.
Via GlobeNewswire
News headline image
High-Flying Biotech Stock Up 360% Faces $48 Million Trim but Remains This Fund's Largest Holding ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This Fund Just Cut a Viridian Stock Position by Over $80 Million. Here's What Investors Should Know ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This Biotech Stock Up 135% Just Faced a $44 Million Trim. Here's What Investors Should Know ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Biotech Stock Up 72% Sees $8 Million Sale, but Here's Why One Fund Still Seems Bullish ↗
Via The Motley Fool
News headline image
Positive VAX-31 Phase 1/2 Adult Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcyte’s 31-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate
From Vaxcyte, Inc.
Via GlobeNewswire
News headline image
The Small-Cap Renaissance: Why the Russell 2000 is Leading the Charge in 2026
Via MarketMinute
Topics Artificial Intelligence Economy Supply Chain
News headline image
Vaxcyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
From Vaxcyte, Inc.
Via GlobeNewswire
News headline image
Vaxcyte Doses First Participants in OPUS-3 Phase 3 Trial Evaluating VAX-31 in Adults Previously Vaccinated with Lower-Valency Pneumococcal Vaccines
From Vaxcyte, Inc.
Via GlobeNewswire
News headline image
Vaxcyte to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on February 24, 2026
From Vaxcyte, Inc.
Via GlobeNewswire
News headline image
Vaxcyte to Present at the Guggenheim Emerging Outlook: Biotech Summit
From Vaxcyte, Inc.
Via GlobeNewswire
News headline image
Vaxcyte Announces Closing of $632.5 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
From Vaxcyte, Inc.
Via GlobeNewswire
News headline image
Vaxcyte Announces Pricing of $550 Million Public Offering
From Vaxcyte, Inc.
Via GlobeNewswire
News headline image
Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants
From Vaxcyte, Inc.
Via GlobeNewswire
News headline image
Vaxcyte Advances Adult and Infant Programs for VAX-31, a Potential Best-in-Class, Next-Generation Pneumococcal Conjugate Vaccine
From Vaxcyte, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Vaxcyte, Inc. - Common Stock publicly traded?
Yes, Vaxcyte, Inc. - Common Stock is publicly traded.
What exchange does Vaxcyte, Inc. - Common Stock trade on?
Vaxcyte, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Vaxcyte, Inc. - Common Stock?
The ticker symbol for Vaxcyte, Inc. - Common Stock is PCVX on the Nasdaq Stock Market
What is the current price of Vaxcyte, Inc. - Common Stock?
The current price of Vaxcyte, Inc. - Common Stock is 48.56
When was Vaxcyte, Inc. - Common Stock last traded?
The last trade of Vaxcyte, Inc. - Common Stock was at 06/05/26 11:23 AM ET
What is the market capitalization of Vaxcyte, Inc. - Common Stock?
The market capitalization of Vaxcyte, Inc. - Common Stock is 4.55B
How many shares of Vaxcyte, Inc. - Common Stock are outstanding?
Vaxcyte, Inc. - Common Stock has 5B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.